IN2014DN01993A - - Google Patents

Info

Publication number
IN2014DN01993A
IN2014DN01993A IN1993DEN2014A IN2014DN01993A IN 2014DN01993 A IN2014DN01993 A IN 2014DN01993A IN 1993DEN2014 A IN1993DEN2014 A IN 1993DEN2014A IN 2014DN01993 A IN2014DN01993 A IN 2014DN01993A
Authority
IN
India
Prior art keywords
methyl
aminosulfonyl
thiazol
pyridinyl
phenyl
Prior art date
Application number
Other languages
English (en)
Inventor
Wilfried Schwab
Alexander Birkmann
Kurt Vögtli
Dieter Haag
Andreas Lender
Alfons Grunenberg
Birgit Keil
Joachim Rehse
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Publication of IN2014DN01993A publication Critical patent/IN2014DN01993A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/44Acylated amino or imino radicals
    • C07D277/46Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
IN1993DEN2014 2011-09-26 2012-09-26 IN2014DN01993A (enrdf_load_html_response)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11007823A EP2573086A1 (en) 2011-09-26 2011-09-26 N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
PCT/EP2012/068938 WO2013045479A1 (en) 2011-09-26 2012-09-26 N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate

Publications (1)

Publication Number Publication Date
IN2014DN01993A true IN2014DN01993A (enrdf_load_html_response) 2015-05-15

Family

ID=46889067

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1993DEN2014 IN2014DN01993A (enrdf_load_html_response) 2011-09-26 2012-09-26

Country Status (29)

Country Link
US (1) US9340535B2 (enrdf_load_html_response)
EP (3) EP2573086A1 (enrdf_load_html_response)
JP (2) JP6161614B2 (enrdf_load_html_response)
KR (4) KR20180088530A (enrdf_load_html_response)
CN (2) CN103842359B (enrdf_load_html_response)
AR (3) AR088043A1 (enrdf_load_html_response)
AU (2) AU2012314536B2 (enrdf_load_html_response)
BR (1) BR112014003245B1 (enrdf_load_html_response)
CA (1) CA2791142C (enrdf_load_html_response)
CL (1) CL2014000149A1 (enrdf_load_html_response)
DK (2) DK2602258T3 (enrdf_load_html_response)
ES (2) ES2462492T3 (enrdf_load_html_response)
HK (1) HK1220978A1 (enrdf_load_html_response)
HR (1) HRP20140351T1 (enrdf_load_html_response)
IL (2) IL230152A (enrdf_load_html_response)
IN (1) IN2014DN01993A (enrdf_load_html_response)
JO (2) JO3037B1 (enrdf_load_html_response)
MX (2) MX338736B (enrdf_load_html_response)
MY (2) MY190878A (enrdf_load_html_response)
PE (1) PE20141148A1 (enrdf_load_html_response)
PH (2) PH12014500567A1 (enrdf_load_html_response)
PL (2) PL2598501T3 (enrdf_load_html_response)
PT (1) PT2598501E (enrdf_load_html_response)
RU (2) RU2620604C2 (enrdf_load_html_response)
SG (1) SG10201407430TA (enrdf_load_html_response)
TW (2) TWI567070B (enrdf_load_html_response)
UA (2) UA119574C2 (enrdf_load_html_response)
WO (1) WO2013045479A1 (enrdf_load_html_response)
ZA (2) ZA201401773B (enrdf_load_html_response)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2573086A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
EP2573085A1 (en) 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
MX375099B (es) * 2016-04-06 2025-03-06 Innovative Molecules Gmbh Derivados de aminotiazol útiles como agentes antivíricos.
UY37497A (es) * 2016-11-28 2018-06-29 Aicuris Anti Infective Cures Gmbh Formulación tópica que comprende n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida
UY37496A (es) * 2016-11-28 2018-06-29 Aicuris Anti Infective Cures Gmbh Hemihidrato de la base libre de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, métodos de fabricación y usos del mismo
CN117186085A (zh) 2016-11-28 2023-12-08 艾库里斯有限及两合公司 普瑞利韦硫酸盐、其药物制剂、制造方法及治疗疱疹病毒的用途
KR102335327B1 (ko) 2017-04-28 2021-12-03 현대자동차 주식회사 수냉식 이지알 쿨러
US11213516B2 (en) * 2017-06-28 2022-01-04 Aicuris Gmbh & Co. Kg Intravaginally applicable devices comprising antiviral compounds
LT3692039T (lt) 2017-10-05 2023-03-27 Innovative Molecules Gmbh Tiazolų enantiomerai kaip antivirusiniai junginiai
US11964969B2 (en) 2018-07-06 2024-04-23 Phaeno Therapeutics Co., Ltd Crystal forms of thiazole compound and application thereof
AU2019345067A1 (en) * 2018-09-19 2021-04-08 Modernatx, Inc. High-purity peg lipids and uses thereof
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
US20230124969A1 (en) * 2020-03-26 2023-04-20 Aicuris Gmbh & Co. Kg Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3- thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide hemihydrate
CN119731171A (zh) 2022-08-29 2025-03-28 组装生物科学股份有限公司 普瑞利韦的新的结晶形式
WO2024047506A1 (en) 2022-08-29 2024-03-07 Assembly Biosciences, Inc. A novel crystalline form of pritelivir
IL319024A (en) 2022-08-29 2025-04-01 Assembly Biosciences Inc Pharmaceutical preparations for the herpes virus

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2000000109A (es) 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
DE10129714A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Topische Anwendung von Thiazolylamiden
DE10129717A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Kombinationspräparate zur Herpes-Behandlung
DE10129716A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Kombinationspräparate zur Herpes-Behandlung
DE10131128A1 (de) * 2001-06-28 2003-01-16 Bayer Ag Sekundäre Sulfonamide
GB0423653D0 (en) * 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
DE102005014248A1 (de) * 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid
JP2007314516A (ja) * 2006-04-25 2007-12-06 Daiichi Sankyo Co Ltd 2以上の置換基を有するベンゼン化合物を含有する医薬
EA201200423A1 (ru) * 2006-06-09 2012-08-30 Икос Корпорейшн Замещенные фенилуксусные кислоты как dp-2-антагонисты
AR070127A1 (es) * 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
UA103918C2 (en) * 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
EP2573085A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
EP2573086A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate

Also Published As

Publication number Publication date
AR088043A1 (es) 2014-05-07
KR20180088530A (ko) 2018-08-03
JP2014528948A (ja) 2014-10-30
MX2014003389A (es) 2014-07-09
CA2791142A1 (en) 2013-03-26
MX371088B (es) 2020-01-16
MY185063A (en) 2021-04-30
US9340535B2 (en) 2016-05-17
EP2598501A1 (en) 2013-06-05
PT2598501E (pt) 2014-06-25
DK2602258T3 (da) 2014-04-22
HRP20140351T1 (hr) 2014-07-04
WO2013045479A1 (en) 2013-04-04
JP2017114859A (ja) 2017-06-29
KR101768295B1 (ko) 2017-08-14
EP2602258B8 (en) 2016-09-28
RU2620604C2 (ru) 2017-05-29
EP2598501B1 (en) 2014-03-12
AU2015260762A1 (en) 2016-02-04
NZ621615A (en) 2016-04-29
DK2598501T3 (da) 2014-04-22
MX338736B (es) 2016-04-29
JP6353022B2 (ja) 2018-07-04
PH12014500567A1 (en) 2014-04-14
ZA201401773B (en) 2015-12-23
SG10201407430TA (en) 2014-12-30
UA115317C2 (uk) 2017-10-25
BR112014003245A2 (pt) 2017-03-01
NZ718867A (en) 2016-05-27
PL2598501T3 (pl) 2014-08-29
TWI567070B (zh) 2017-01-21
HK1220978A1 (zh) 2017-05-19
EP2602258A1 (en) 2013-06-12
ZA201408734B (en) 2016-08-31
RU2014107430A (ru) 2015-11-10
IL234405A (en) 2015-04-30
AR120291A2 (es) 2022-02-09
AU2012314536A1 (en) 2014-02-06
EP2602258B1 (en) 2014-03-19
ES2462492T3 (es) 2014-05-23
JO3734B1 (ar) 2021-01-31
RU2669388C1 (ru) 2018-10-11
AU2012314536B2 (en) 2016-01-14
TW201625603A (zh) 2016-07-16
KR20170055565A (ko) 2017-05-19
US20140221433A1 (en) 2014-08-07
PH12015502801B1 (en) 2016-10-03
PE20141148A1 (es) 2014-09-15
PL2602258T3 (pl) 2014-08-29
TWI532739B (zh) 2016-05-11
JP6161614B2 (ja) 2017-07-12
CA2791142C (en) 2017-08-01
UA119574C2 (uk) 2019-07-10
TW201317234A (zh) 2013-05-01
PH12015502801A1 (en) 2016-10-03
ES2466221T3 (es) 2014-06-09
AR116394A2 (es) 2021-05-05
JO3037B1 (ar) 2016-09-05
KR20140066704A (ko) 2014-06-02
CN105541829A (zh) 2016-05-04
EP2573086A1 (en) 2013-03-27
BR112014003245B1 (pt) 2021-11-09
CN103842359B (zh) 2016-05-25
MY190878A (en) 2022-05-13
CN103842359A (zh) 2014-06-04
KR20190104249A (ko) 2019-09-06
ES2466221T8 (es) 2016-09-13
AU2015260762B2 (en) 2016-06-09
IL230152A (en) 2015-04-30
CL2014000149A1 (es) 2014-09-05

Similar Documents

Publication Publication Date Title
IN2014DN01993A (enrdf_load_html_response)
EA201001683A1 (ru) Производные фенил- или пиридинилзамещенных индазолов
PH12013501704A1 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
TN2011000400A1 (en) Inhibitors of beta-secretase
MY165087A (en) Neprilysin inhibitors
TN2016000210A1 (en) Urea derivative or pharmacologically acceptable salt thereof.
MX348654B (es) Composicion farmaceutica con biodisponibilidad mejorada para compuesto hidrofobico de alto punto de fusion.
PH12013501557A1 (en) Glucagon receptor modulator
NZ707389A (en) Process for preparing bile acid derivatives
IN2014CN04530A (enrdf_load_html_response)
EA201270216A1 (ru) Фармацевтический состав
EA201291217A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ
MX2013005241A (es) Cristal de derivado de 6,7-insaturado-7-carbamoil morfinano y metodo para producir el mismo.
IN2014DN01992A (enrdf_load_html_response)
ATE500222T1 (de) Benzamid- und heteroarenderivate als cetp- inhibitoren
CR20130501A (es) Derivados novedosos de cefalosporinas y composiciones farmacéuticas de estos
MX2010006787A (es) Análogos halogenados de agentes anti-fibroticos.
IN2014DN01629A (enrdf_load_html_response)
MX2013006768A (es) Moduladores de receptor de glucagon.
MY149973A (en) 3-carboxypropyl-aminotetralin derivatives as mu opioid receptor antagonists
UA116877C2 (uk) Сполука з антибактеріальною і/абопротивірусною активністю
MX364529B (es) Nuevos ligandos del receptor de estrógeno.
PH12012000124A1 (en) Synthesis process, and crystalline form of 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide hydrochloride and pharmaceutical compositions containing it
MX2013012773A (es) Sustancias farmacologicas, composiciones farmaceuticas y metodos para la preparacion de las mismas.
MX2014000855A (es) Moduladores receptores de glucagon de quinolinilo.